Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Applying amide proton transfer‐weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas

Open access
Ma, Bo, Blakeley, Jaishri O., Hong, Xiaohua, Zhang, Hongyan, Jiang, Shanshan, Blair, Lindsay, Zhang, Yi, Heo, Hye‐Young, Zhang, Mingzhi, van Zijl, Peter C. M., Zhou, Jinyuan·2016·Journal of Magnetic Resonance Imaging

Abstract

Purpose: To assess amide proton transfer‐weighted (APTW) imaging features in patients with malignant gliomas after chemoradiation and the diagnostic performance of APT imaging for distinguishing true progression from pseudoprogression. Materials and Methods: After approval by the Institutional Review Board, 32 patients with clinically suspected tumor progression in the first 3 months after chemoradiation were enrolled and scanned at 3T. Longitudinal routine magnetic resonance imaging (MRI) changes and medical records were assessed to confirm true progression versus pseudoprogression. True progression was defined as lesions progressing on serial imaging over 6 months, and pseudoprogression was defined as lesions stabilizing or regressing without intervention. The APTW mean and APTW max signals were obtained from three to five regions of interests for each patient and compared between the true progression and pseudoprogression groups. The diagnostic performance was assessed with receiver operating characteristic curve analysis. Results: The true progression was associated with APTW hyperintensity (APTW mean = 2.75% ± 0.42%), while pseudoprogression was associated with APTW isointensity to mild hyperintensity (APTW mean = 1.56% ± 0.42%). The APTW signal intensities were significantly higher in the true progression group (n = 20) than in the pseudoprogression group (P < 0.001; n = 12). The cutoff APTW mean and APTW max intensity values to distinguish between true progression and pseudoprogression were 2.42% (with a sensitivity of 85.0% and a specificity of 100%) and 2.54% (with a sensitivity of 95.0% and a specificity of 91.7%), respectively. Conclusion: The APTW‐MRI signal is a valuable imaging biomarker for distinguishing pseudoprogression from true progression in glioma patients. J. Magn. Reson. Imaging 2016;44:456–462.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jmri.25159

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 173

Metadata

Authors
Ma, B., Blakeley, J. O., Hong, X., Zhang, H., Jiang, S., Blair, L., Zhang, Y., Heo, H., Zhang, M., van Zijl, P. C. M., & Zhou, J.
Venue
Journal of Magnetic Resonance Imaging
Publisher
Wiley
Published
2016-01-20
Volume
44
Issue
2
Pages
456-462
ISSN
  • 1053-1807 (ISSN-L)
  • 1522-2586
OpenAlex
W2337474457
Cited by
173
References
1
FWCI
9.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Applying amide proton transfer‐weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. https://app.cochat.ai/papers/10.1002/jmri.25159
The paper
Ma, B., Blakeley, J. O., Hong, X., Zhang, H., Jiang, S., Blair, L., Zhang, Y., Heo, H., Zhang, M., van Zijl, P. C. M., & Zhou, J. (2016). Applying amide proton transfer‐weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.25159

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.